Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Ross, Amanda ^a,b   Maire, Nicolas ^a,b   Sicuri, Elisa ^c,d   Smith, Thomas ^a,b   Conteh, Lesong ^e  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISEASE TRANSMISSION; DRUG COST; GENE MUTATION; GENOTYPE; HEALTH CARE COST; HUMAN; MALARIA; MALARIA CONTROL; MORTALITY; PLASMODIUM FALCIPARUM; PREVENTIVE MEDICINE; SEASONAL VARIATION; SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INFANT; MALARIA FALCIPARUM; MALE; PRESCHOOL CHILD; THEORETICAL MODEL;

PLASMODIUM FALCIPARUM;

ANTIMALARIALS; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; MALARIA; MALARIA, FALCIPARUM; MALE; MODELS, THEORETICAL;

EID: 79954514099     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018391     Document Type: Article

References (89)

1. World Health Organization (2009) World malaria report 2009. Geneva, WHO.
2. Asenso-Okyere W, Dzator J, (1997) Household cost of seeking malaria care. A retrospective study of two malaria districts in Ghana. Soc Sci Med 45: 659-667.
3. Deressa W, Hailemariam D, Ali A, (2007) Economic costs of epidemic malaria to households in rural Ethiopia. Trop Med Int Health 12: 1148-1156.
4. Wiseman V, McElroy B, Conteh L, Stevens W, (2006) Malaria prevention in The Gambia: patterns of expenditure and determinants of demand at the household level. Trop Med Int Health 11: 419-431.
5. Owusu-Agyei S, Awini E, Anto F, Mensah-Afful T, Adjuik M, et al. (2007) Assessing malaria control in the Kassena-Nankana district of northern Ghana through repeated surveys using the RBM tools. Malar J 6: 103.
6. Kiszewski A, Johns B, Schapira A, Delacollette C, Crowell V, et al. (2007) Estimated global resources needed to attain international malaria goals. Bull WHO 85: 623-630.
7. Sachs J, (2001) Macroeconomics and health: investing in health for economic development. Geneva, WHO.
8. Egan A, Crawley J, Schellenberg D, (2005) Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health 10: 815-817.
9. Greenwood B, (2006) Review: intermittent preventive treatment- a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 11: 983-991.
10. Grobusch M, Egan A, Gosling R, Newman R, (2007) Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 20: 613-620.
11. O'Meara W, Breman J, McKenzie F, (2005) The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J 4: 33.
12. Manzi F, Schellenberg J, Hamis Y, Mushi A, Shirima K, et al. (2009) Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants: the development and implementation of a public health strategy. Trans Roy Soc Trop Med Hyg 103: 79-86.
13. Manzi F, Hutton G, Schellenberg J, Tanner M, Alonso P, et al. (2008) From strategy development to routine implementation: the cost of intermittent preventive treatment in infants for malaria control. BMC Health Services Res 8: 165.
14. Konaté A, Yaro J, Ouédraogo A, Diarra A, Gansané A, et al. (2011) Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide treated bednet in Burkina Faso: A randomised, double-blind, placebo-controlled trial PLoS Med 8: e1000408.
15. Dicko A, Diallo A, Tembine I, Dicko Y, Dara N, et al. (2011) Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide treated bednet in Mali: A randomised, double-blind, placebo-controlled trialPLoS Med 8: e1000407.
16. Sokhna C, Cissé B, Ba E, Milligan P, Hallett R, et al. (2008) A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS ONE 3: e1471.
17. Cisse B, Sokhna C, Boulanger D, Milet J, Ba E, et al. (2006) Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367: 659-667.
18. Cisse B, Cairns M, Faye E, NDiaye O, Faye B, et al. (2009) Randomized trial of piperaquine with sulphadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS ONE 4: e7164.
19. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, et al. (2008) Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo-controlled trial. PLoS ONE 3: e4000.
20. Kweku M, Webster J, Adjuik M, Abudey S, Greenwood B, Chandramohan D, (2010) Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial PLoS ONE 4: e7256.
21. Bojang K, Akor F, Conteh L, Webb E, Bittaye O, et al. (2011) Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in The Gambia: A randomised controlled trial PLoS Med 8: e1000409.
22. Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, et al. (2010) A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS ONE 5: e11225.
23. Dicko A, Sagara I, Sissoko M, Guindo O, Diallo A, et al. (2008) Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 7: 123.
24. Barger B, Maiga H, Traore H, Tekete M, Tembine I, et al. (2009) Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali. Trop Med Int Health 14: 784-791.
25. Clarke S, Jukes M, Njagi J, Khasakhala L, Cundill B, et al. (2008) Effect of intermittent preventive treatment of malaria on health and education in schoolchildren: a cluster-randomized, double-blind, placebo-controlled trial. Lancet 372: 127-138.
26. Temperley M, Mueller D, Njagi J, Akhwale W, Clarke S, et al. (2008) Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya. Malar J 7: 196.
27. Rohner F, Zimmerman M, Amon R, Vounatsou P, Tschanen A, et al. (2010) In a randomized controlled trial of iron fortification, anthelminthic treatment, and intermittent preventive treatment of malaria for anemia control in Ivorian children, only anthelminthic treatment shows modest benefit. J Nutr 140: 635-641.
28. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. (2005) Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727-733.
29. Grobusch M, Lell B, Schwarz N, Gabor J, Dornemann J, et al. (2006) Intermittent preventive treatment against infants in Gabon- a randomized, double-blind, placebo-controlled trial. J Inf Dis 196: 1595-1602.
30. Macete E, Aide P, Aponte J, Sanz S, Mandomando I, et al. (2006) Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Inf Dis 194: 276-285.
31. Mockenhaupt F, Reither K, Zanger P, Roepcke F, Danquah I, et al. (2007) Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 51: 3273-3281.
32. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial Lancet 357: 1471-1477.
33. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, et al. (2007) A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants Clin Inf Dis 45: 16-25.
34. Aponte J, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials Lancet 374: 1533-1542.
35. Gosling R, Gesase S, Mosha J, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, placebo-controlled trial Lancet 374: 1521-1532.
36. Odhiambo F, Hamel M, Williamson J, Lindblade K, ter Kuile F, et al. (2010) Intermittent preventive treatment in infants for the prevention of malaria and anaemia in rural Western Kenya: a randomized, double-blind, placebo-controlled trial. PLoS ONE 5: e10016.
37. Sesay S, Milligan P, Touray E, Sowe M, Webb E, et al. (2011) A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia. Malar J 10: 2.
38. Tagbor H, Cairns M, Nakwa E, Browne E, Sarkodie B, et al. (2011) The clinical impact of combining intermittent preventive treatment with home management of malaria in children aged below 5 years: cluster randomised trial. Trop Med Int Health (published online).
39. Wilson A on behalf of the IPTc Taskforce (2010) A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc) PLoS ONE 6: e16976.
40. Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, et al. (2010) The cost-effectiveness of intemittent preventive treatment in infants in sub-Saharan Africa PLoS ONE 5: e10313.
41. Hutton G, Schellenberg D, Tediosi F, Macete E, Kahigwa E, et al. (2009) Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania Bull WHO 87: 123-129.
42. Conteh L, Patouillard E, Kweku M, Legood R, Greenwood B, et al. (2010) The cost-effectiveness of intermittent preventive treatment in children (IPTc) using amodiaquine and artesunate versus sulphadoxine-pyrimethamine in Hohoe district, Ghana PLoS ONE 5: e12223.
43. McGready R, (2009) Intermittent preventive treatment of malaria in infancy. Lancet 374: 1478-1480.
44. Buffet P, Briand V, Rénia L, Thellier M, Danis M, et al. (2008) Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap? Trends Parasitol 24: 482-485.
45. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, et al. (2007) Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop Med Int Health 12: 1-8.
46. de Sousa A, Salama P, Chopra M, (2010) Implementing intermittent preventive treatment in infants. Lancet 375: 121.
47. Beeson J, Rogerson S, Mueller I, Richards J, Fowkes F, (2011) Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and delivery PLoS Med 8: e1000410.
48. Smith T, Killeen GF, Maire N, Ross A, Molineaux L, et al. (2006) Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview. Am J Trop Med Hyg75 (Suppl 2): 1-10.
49. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, et al. (2006) A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas. Am J Trop Med Hyg75 (Suppl 2): 19-31.
50. Smith T, Ross A, Maire N, Rogier C, Trape JF, et al. (2006) An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria. Am J Trop Med Hyg75 (Suppl 2): 56-62.
51. Ross A, Maire N, Molineaux L, Smith T, (2006) An epidemiologic model of severe morbidity and mortality caused by Plasmodium falciparum. Am J Trop Med Hyg75 (Suppl 2): 63-73.
52. Smith T, Maire N, Ross A, Penny M, Chitnis N, et al. (2008) Towards a comprehensive simulation model of malaria epidemiology and control Parasitol 135: 1507-1516.
53. Ross A, Penny M, Maire N, Studer A, Carneiro I, et al. (2008) Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants PLoS ONE 3: e2661.
54. Hastings I, Watkins WM, (2006) Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 22: 71-77.
55. Orrell C, Little F, Smith P, Folb P, Taylor W, et al. (2008) Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers Eur J Clin Pharmacol 64: 683-690.
56. Pussard E, Verdier F, Faurisson F, Schermann J, Le Bras J, et al. (1987) Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Phamacol 33: 409-414.
57. Winstanley P, Simooya O, Kofi-Ekue J, Walker O, Salako L, et al. (1990) The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol 29: 695-701.
58. Patouillard E, Conteh L, Webster J, Kweku M, Greenwood B, Chandramohan D, (2011) Coverage and costs of two different systems for delivering intermittent preventive treatment of malaria to Ghaian children. In prep.
59. International drug price indicator guide (2007) 18 Available: http://erc.msh.org/dmpguide/Accessed 2011 Mar.
60. Tediosi F, Maire N, Penny M, Studer A, Smith T, (2009) Simulation of the cost-effectiveness of malaria vaccines. Malar J 8: 127.
61. Bureau of Labor Statistics (2010) CPI Inflation calculator. 18 Available: http://www.bls.gov/data/inflation_calculator.htm Accessed 2011 Mar.
62. Penny M, Maire N, Studer A, Schapira A, Smith T, (2008) What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE 3: e3193.
63. Tediosi F, Hutton G, Maire N, Smith T, Ross A, et al. (2006) Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. Am J Trop Med Hyg75 (2 Suppl): 131-143.
64. Gold M, Gold S, Weinstein M, (1996) Cost-effectiveness in health and medicine. New York Oxford University Press.
65. Weinstein M, Siegel J, Gold M, Kamlet M, Russell L, (1996) Recommendations of the panel of cost-effectiveness in medicine. JAMA 276: 1253-1341.
66. Murray C, Lopez A, (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard Harvard University Press.
67. Fox-Rushby J, Hanson K, (2001) Calculating and presenting disability-adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 16: 326-331.
68. Shillcutt S, Walker D, Goodman C, Mills A, (2009) Cost-effectiveness in low- and middle- income countries: a review of the debates surrounding the decision rules. Phamacoecon 27: 903-917.
69. World Bank (1993) World development report. Washington, DC 1993.
70. Carneiro I, Roca-Feltrer A, Griffin J, Smith L, Tanner M, et al. (2010) Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS ONE 5: e8988.
71. Vinetz J, (2010) Intermittent preventive treatment for malaria in sub-Saharan Africa: a halfway technology or a critical intervention? Am J Trop Med Hyg82: 755-756.
72. Trape J, Rogier C, (1996) Combating malaria morbidity and mortality by reducing transmission. Parasitol Today 12: 236-240.
73. Yukich J, Lengeler C, Tediosi F, Brown N, Mulligan J, et al. (2008) Costs and consequences of large-scale vector control for malaria. Malar J 7: 258.
74. Morel C, Lauer J, Evans D, (2005) Achieving millenium development goals for health: cost-effectiveness analysis of strategies to combat in developing countries. BMJ 331: 1299.
75. Goodman C, Coleman P, Mills A, (2000) Economic analysis of malaria control in sub-Saharan Africa. Geneva, Global Forum for Health Research.
76. Gosling R, Ghani A, Deen J, von Seidlein L, Greenwood B, et al. (2008) Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J 7: 54.
77. Aguas R, Lourenço J, Gomes M, White L, (2009) The impact of IPTi and IPTc interventions on malaria clinical burden- in silico perspectives. PLoS ONE 4: e6627.
78. Aponte J, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, et al. (2007) Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 4: e359.
79. Meremikwu M, Donegan S, Esu E, (2008) Chemoprophylaxis and intermittent treatment for preventing malaria in children (review). Cochrane Database Syst Rev 2008 Apr (16): CD003756.
80. Smith T, Maire N, Dietz K, Killeen G, Vounatsou P, et al. (2006) Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg75 (Suppl 2): 11-18.
81. Ross A, Smith T, (2006) The effect of malaria transmission intensity on neonatal mortality in endemic areas. Am J Trop Med Hyg. 75 (Suppl 2): 74-81.
82. Ross A, Killeen G, Smith T, (2006) Relationships between host infectivity to mosquitoes and asexual parasite density in Plasmodium falciparum. Am J Trop Med Hyg75 (Suppl 2): 32-37.
83. Killeen G, Ross A, Smith T, (2006) Infectiousness of malaria-endemic human populations to vectors. Am J Trop Med Hyg75 (2 Suppl): 38-45.
84. Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, et al. (2006) An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-Saharan Africa. Am J Trop Med Hyg75 (Suppl 2): 90-103.
85. Arnesen T, Nord E, (1999) The value of DALY life: problems with ethics and validity of disability-adjusted life years. BMJ 319: 1423-1425.
86. Anand S, Hanson K, (1997) Disability-adjusted life years: a critical review. J Health Econ 16: 685-702.
87. Arnesen T, Kapiriri L, (2004) Can the value choices in DALYs influence global health priorities? Health Policy 70: 137-149.
88. Mathers C, Salomon J, Ezzati M, Begg S, vander Hoorn S, et al. (2006) Sensitivity and uncertainty analyses for burden of disease and risk factor estimates. Global burden of disease and risk factors. New York Oxford University Press pp. 399-426.
89. Robert V, Dieng H, Lochouarn L, Traoré S, Simondon F, et al. (1998) La transmission du paludisme dans la zone de Niakhar, Sénégal. Trop Med Int Health.3: 667-677.